Deciphering Bone Microarchitecture in Diabetic Charcot Neuroarthropathy of Foot: A Case Control Study
- PMID: 40917315
- PMCID: PMC12410952
- DOI: 10.4103/ijem.ijem_51_25
Deciphering Bone Microarchitecture in Diabetic Charcot Neuroarthropathy of Foot: A Case Control Study
Abstract
Introduction: Charcot neuroarthropathy (CNO) of foot characterised by an increased bone turnover denoted by serological markers of bone resorption. However, histological characteristics of foot bones in people with CNO are not well elucidated.
Methods: The foot bone samples were collected from patients who had either surgical reconstruction or below-knee amputations for chronic CNO foot (n = 10, Group A), unsalvageable diabetic foot ulcer (n = 16, Group B), and non-diabetic healthy controls following road traffic accident (n = 16, group C). Calcaneum bones retrieved were processed and sections (Haemotoxylin and Eosin, Masson-Goldner stain) evaluated for quantitative histopathological parameters including bony trabeculae number, trabeculae thinning, osteoclast number, Howship's lacunae, and Haversian canal.
Results: The mean age of participants in the CNO group was 61.6 ± 5.0 and 62.9 ± 6.5 years in diabetic neuropathy group with duration of diabetes 13.1 ± 6.8 and 14.1 ± 9.1 years with HbA1c of 7.6 ± 1.8% and 8.7 ± 2.6 in group A and B, respectively. We observed that normal bone trabeculae were 15% (10-37.5) in group A and 60% (47.5-82.5) in group B as compared to controls (P = <0.001). Thin bone trabeculae (%) were observed in 10% (3.5-77.5) and 7.5% (0-30), P =<0.001), with increased Howship's lacunae number (1.5 [0.25-2] and 1 [0-2.25] (P = <0.001)) and increased osteoclast number in group A and B as compared to healthy controls.
Conclusions: There is an increased bone resorption in CNO causing thinning of bone trabeculae secondary to increased osteoclast numbers and Howship's lacunae in CNO of foot. Anti-resorptive therapies that target osteoclast activity may be an appealing treatment option for diabetic CNO of foot.
Keywords: BTM; CNO; DFU; H and E; histopathology.
Copyright: © 2025 Indian Journal of Endocrinology and Metabolism.
Conflict of interest statement
There are no conflicts of interest.
Figures


References
-
- Wukich DK, Schaper NC, Gooday C, Bal A, Bem R, Chhabra A, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023) Diabetes Metab Res Rev. 2024;40:e3646. - PubMed
-
- Chaudhary S, Bhansali A, Rastogi A. Mortality in Asian Indians with Charcot's neuroarthropathy: A nested cohort prospective study. Acta Diabetol. 2019;56:1259–64. - PubMed
-
- Rastogi A, Prakash M, Bhansali A. Varied presentations and outcomes of Charcot neuroarthropathy in patients with diabetes mellitus. Int J Diabetes Dev Ctries. 2019;39:513–22.
-
- Jeffcoate W, Game F. The Charcot foot reflects a response to injury that is critically distorted by preexisting nerve damage: An imperfect storm. Diabetes Care. 2022;45:1691–7. - PubMed
LinkOut - more resources
Full Text Sources